Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
804,525
-
Total 13F shares
-
115,809
-
Share change
-
-17,165
-
Total reported value
-
$234,131
-
Price per share
-
$2.00
-
Number of holders
-
10
-
Value change
-
-$203,650
-
Number of buys
-
8
-
Number of sells
-
6
Institutional Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q4 2022
As of 31 Dec 2022,
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
115,809 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, Virtu Financial LLC, UBS Group AG, BlackRock Inc., AllSquare Wealth Management LLC, Federation des caisses Desjardins du Quebec, NATIONAL BANK OF CANADA /FI/, Advisory Services Network, LLC, TCI Wealth Advisors, Inc., and GABLES CAPITAL MANAGEMENT INC..
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.